EneBio

EneBio is a South Korean biotechnology company specializing in the development of next-generation Live Biotherapeutic Products (LBPs) and microbiome-based therapeutics. Founded by experts in microbiology and immunology, the company focuses on identifying specific microbial strains that can modulate the host immune system to treat oncology and inflammatory conditions. Its lead program, EB-101, is being evaluated in clinical trials as a combination therapy with immune checkpoint inhibitors for patients with non-small cell lung cancer. EneBio's proprietary platform integrates metagenomic analysis with advanced immunological screening to accelerate the discovery of efficacious microbial candidates. By targeting the gut-lung and gut-brain axes, the company aims to provide novel treatment options for diseases with significant unmet medical needs.